Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q1 CY2025 results exceeding the market’s revenue expectations , with sales up 19.5% year on year to $1.05 billion. Its non-GAAP profit of $1.16 per share was 10.6% above analysts’ consensus estimates.

Is now the time to buy INCY? Find out in our full research report (it’s free).

Incyte (INCY) Q1 CY2025 Highlights:

Revenue: $1.05 billion vs analyst estimates of $989.2 million (19.5% year-on-year growth, 6.4% beat) Adjusted EPS: $1.16 vs analyst estimates of $1.05 (10.6% beat) Adjusted EBITDA: $227.5 million vs analyst estimates of $279.3 million (21.6% margin, 18.5% miss) Operating Margin: 19.5%, up from 10.4% in the same quarter last year Free Cash Flow Margin: 27.9%, up from 23.8% in the same quarter last year Market Capitalization: $11.78 billion

StockStory’s Take

Incyte’s first quarter results reflected notable commercial momentum and pipeline advancement, with management attributing much of the company’s performance to strong demand for Jakafi and the initial launch of Niktimvo. CEO Herve Hoppenot highlighted the successful rollout of Niktimvo in chronic graft-versus-host disease, as well as ongoing growth in Jakafi’s polycythemia vera indication. Management also emphasized the positive impact of expanded formulary coverage for Opzelura, now preferred on two of the three largest pharmacy benefit manager formularies, resulting in broader patient access and higher net product revenue.

Looking ahead, Incyte’s leadership outlined several key revenue drivers. Hoppenot pointed to three additional planned product launches in 2025, continued progress in late-stage clinical studies, and several pivotal data readouts as critical to sustaining growth. CFO Christiana Stamoulis reaffirmed increased full-year guidance for Jakafi, citing favorable gross-to-net dynamics and persistent patient demand. Management also addressed tariff concerns, stating that dual US and European manufacturing provides flexibility, minimizing potential impacts from trade policy changes.

Key Insights from Management’s Remarks

Incyte’s management detailed a quarter shaped by strong product demand, expanding market access, and pipeline milestones. Key topics included new product launches, growth in core franchises, and the impact of healthcare policy changes.

Jakafi growth in polycythemia vera: Management cited robust volume increases for Jakafi, especially in the polycythemia vera indication, supported by early intervention data and effective physician education campaigns. They expect polycythemia vera to become the largest driver for Jakafi over time. Opzelura’s expanded access: The addition of Opzelura to Optum Premium’s preferred formulary improved its commercial coverage to 94%, enhancing growth prospects for both atopic dermatitis and vitiligo indications. Niktimvo launch momentum: The launch of Niktimvo for chronic graft-versus-host disease exceeded initial expectations, with rapid uptake across leading bone marrow transplant centers. Management noted that 95% of top centers have used the product. Pipeline data readouts: Positive phase 2 and phase 3 clinical data for pipeline assets such as povorcitinib in hidradenitis suppurativa and chronic spontaneous urticaria were highlighted, with management aiming for three additional product launches in 2025. Tariff risk mitigation: Management explained that dual sourcing and geographically diversified manufacturing reduce the impact of potential pharmaceutical tariffs, while inventory levels for at-risk inputs remain sufficient to support near-term supply needs.

Story Continues

Drivers of Future Performance

Management’s outlook for the next several quarters focuses on continued product launches, new clinical data, and operational efficiency as the main themes underpinning future performance.

Multiple product launches ahead: The company expects three more launches in 2025, which management believes will materially expand the commercial portfolio and near-term revenue base. Advancing pipeline milestones: Several late-stage and pivotal clinical trials are on track for readouts this year, including phase 3 studies in dermatology and oncology, which could broaden Incyte’s approved indications and market reach. Operational flexibility and risk management: Diversified manufacturing and inventory strategies are expected to safeguard supply continuity, while management cited ongoing investments in R&D and commercial infrastructure as essential for long-term growth.

Top Analyst Questions

Michael Schmidt (Guggenheim): Asked how much Jakafi’s polycythemia vera growth is driven by new patient starts versus ongoing therapy; management noted both contribute, with new patient education and persistence supporting future expansion. David Lebowitz (Citi): Inquired about povorcitinib’s positioning in chronic spontaneous urticaria relative to biologics; management responded it could serve both pre- and post-biologic patient populations, with some preferring an oral option first. Salveen Richter (Goldman Sachs): Sought details on Opzelura’s growth by indication and steps to improve access for atopic dermatitis; management described stable growth across both indications and ongoing efforts to expand formulary coverage and patient support services. Jessica Fye (JPMorgan): Asked about capital allocation and the potential for further share repurchases; management emphasized prioritizing pipeline investment, with business development focused on early-stage partnerships. Madeline (William Blair): Queried whether positive phase 2 data in chronic spontaneous urticaria alters Incyte’s plans for other related programs; management noted satisfaction with current pipeline progress, with no plans to restart previously discontinued programs.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will be monitoring (1) the pace and breadth of new product launches and their initial market adoption, (2) the timing and outcome of late-stage clinical data readouts, particularly in dermatology and oncology, and (3) the continued expansion of commercial coverage for Opzelura and other key products. Execution on these initiatives, along with effective supply chain management amid evolving tariff risks, will be critical for tracking Incyte’s strategic progress.

Incyte currently trades at a forward P/E ratio of 10.3×. Should you load up, cash out, or stay put? The answer lies in our free research report.

High-Quality Stocks for All Market Conditions

The market surged in 2024 and reached record highs after Donald Trump’s presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025.

While the crowd speculates what might happen next, we’re homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver’s seat and build a durable portfolio by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

View Comments